Nymox posts $4.3M loss, flags going-concern risk
NYMXF remains a pre‑revenue biotech with heavy losses, severe liquidity constraints, going‑concern uncertainty and key NX‑1207 regulatory decisions still pending.
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
20-F
Rhea-AI Filing Summary
Nymox Pharmaceutical Corporation (NYMXF) filed its annual Form 20‑F detailing continued development-stage operations with no revenues and ongoing losses. For 2025, the company reported a net loss of $4.3 million, total assets of about $576,000, and an accumulated deficit of roughly $216.7 million.
Cash was only $6,000 at December 31 2025 against a negative working capital position of about $9.3 million, and both management and the auditor highlight a material uncertainty about the company’s ability to continue as a going concern. Nymox remains pre‑revenue, developing its lead drug fexapotide triflutate (NX‑1207) for benign prostatic hyperplasia and low‑grade prostate cancer. Earlier Phase 3 BPH trials initially failed primary endpoints at 12 months but later met a long‑term symptomatic endpoint in extension studies.
The company has faced regulatory setbacks, including an FDA Refusal to File letter in 2022 and a Danish Marketing Authorization Application that lapsed and would require resubmission with a new fee, while a U.K. MAA remains under review. Operations are funded primarily through equity and related‑party financing, with 102,040,140 shares outstanding at year‑end 2025 and significant option overhang. Insiders and directors, led by CEO Paul Averback, beneficially control just over 55% of the shares.
Positive
- None.
Negative
- Material going-concern uncertainty: Management and the auditor state that recurring losses, shareholders’ deficit and a $9.3 million working capital deficit cast substantial doubt on the ability to continue as a going concern.
- Very weak liquidity: Cash was only $6,000 at December 31 2025, while cash used in operations was $1.8 million in 2025, implying urgent need for additional financing.
- No revenues and persistent losses: Nymox reported zero revenue for at least 2021‑2025 and a 2025 net loss of $4.3 million, with an accumulated deficit of about $216.7 million since inception.
- Regulatory setbacks for NX‑1207: An FDA Refusal to File letter was received in May 2022, the Danish MAA ran out of time and requires resubmission with a new fee, and the U.K. MAA is under review with outcome uncertain.
- Significant dilution risk: The business plan relies heavily on equity financing; there were 105,040,140 shares outstanding by September 9 2026 plus 14,375,000 options outstanding, many already vested.
- High ownership concentration: CEO Paul Averback beneficially controls 44.9% of shares, and directors and officers as a group control 55.1%, limiting minority shareholder influence.
